ARGX
Argenx SE is a commercial-stage immunology company developing monoclonal antibodies for rare autoimmune diseases. Its lead approved product, VYVGART (efgartigimod alfa-fcab), is available intravenously and subcutaneously for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with additional approvals in Japan for immune thrombocytopenia. The company markets VYVGART under regional brand names including VYVGART HYTRULO in the U.S. and China, and VYVDURA in Japan.
Pipeline
Intravenous formulation of efgartigimod (Vyvgart): antibody Fc fragment that blocks FcRn to lower circulating IgG. Approved in generalized myasthenia gravis.
Subcutaneous co-formulation of efgartigimod with hyaluronidase (Vyvgart Hytrulo): FcRn inhibitor antibody fragment. Approved in generalized myasthenia gravis and CIDP.
Anti-C2 monoclonal antibody (ARGX-117, argenx) that blocks the classical complement pathway. Phase 3 in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN).
Intravenous empasiprubart (ARGX-117): anti-C2 monoclonal antibody blocking classical complement. Phase 2 in generalized myasthenia gravis, dermatomyositis, and myositis.
Intravenous immunoglobulin: pooled human polyclonal IgG used as immunomodulator/replacement therapy. Standard of care in CIDP, multifocal motor neuropathy, ITP, and primary immunodeficiency.
Intravenous immunoglobulin: pooled human polyclonal IgG used as immunomodulator/replacement therapy. Standard of care in CIDP, MMN, ITP, and primary immunodeficiency.
Subcutaneous co-formulation of efgartigimod with hyaluronidase: FcRn inhibitor antibody fragment. Under investigation in dermatomyositis, myositis, and primary Sjögren's disease.
argenx code name for empasiprubart: anti-C2 monoclonal antibody blocking classical complement. Phase 3 in CIDP and MMN; Phase 2 in additional indications.
argenx anti-MuSK agonist monoclonal antibody. Strengthens neuromuscular junction signaling. Phase 2 in DOK7-CMS and amyotrophic lateral sclerosis.
Intravenous ARGX-119: anti-MuSK agonist antibody that strengthens neuromuscular junction signaling. Phase 2 in spinal muscular atrophy and ALS.